IMV Inc. (IMVIF)

Market Cap	29.42K -99.9%
Revenue (ttm)	n/a
Net Income	-37.99M
EPS	-4.55
Shares Out	14.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,741
Average Volume	6,416
Open	0.0020
Previous Close	n/a
Day's Range	0.0020 - 0.0020
52-Week Range	n/a
Beta	4,526.03
RSI	52.27
Earnings Date	n/a

About IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 63
• Stock Exchange: OTCMKTS
• Ticker Symbol: IMVIF